RecruitingNot ApplicableNCT06274957

The Effect of Airway and Chest Wall Oscillation on Respiratory Functions in COPD Patients in Acute Exacerbation

The Effect of Airway Oscillation and Chest Wall Oscillation on Respiratory Functions and Sleep Quality in COPD Patients in Acute Exacerbation Period and Technical Inspection of Devices


Sponsor

Saglik Bilimleri Universitesi

Enrollment

27 participants

Start Date

May 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Chronic obstructive pulmonary disease (COPD); It is a common, treatable and preventable disease characterized by progressive and irreversible airflow limitation and has systemic effects with respiratory system involvement. Increased respiratory workload, decreased work .


Eligibility

Min Age: 40 Years

Inclusion Criteria4

  • Being classified as GOLD stage 3 or 4 based on spirometric evaluation in the medical history.
  • Having a hospital admission within the specified time frame, evaluated by a pulmonary specialist, and admitted to the pulmonary diseases service with a diagnosis of COPD exacerbation.
  • Being 40 years of age or older.
  • Voluntarily agreeing to participate in the study.

Exclusion Criteria13

  • Having a hospital admission with a diagnosis of asthma attack in the last 5 years.
  • Monitoring suspicious focal points for pneumonia on lung radiology.
  • Hospitalization due to reasons other than exacerbation despite having a diagnosis of COPD.
  • Presence of pulmonary fibrosis or suspicious findings of fibrosis on radiology.
  • Systemic fungal infections.
  • Having cognitive impairment affecting the decision to participate in the study, such as confusion, orientation disorder, or dementia.
  • Patients with lung cancer or metastasis in the lungs.
  • Diagnosis of conditions provoking shortness of breath other than COPD exacerbation, such as pneumonia, pneumothorax, heart failure, and pulmonary embolism.
  • Presence of a new-onset rhythm disorder or ischemic changes requiring intervention on the EKG, excluding sinus tachycardia and multifocal atrial tachycardia.
  • Chronic kidney failure requiring hemodialysis.
  • Patients with conditions causing weakness in the lower extremities, such as arthritis, neurological disease, deep vein thrombosis, peripheral artery disease, muscle weakness, fractures, osteoarthritis, etc.
  • Having ankylosing spondylitis with a Cobb angle of 10 degrees or more in the radiographic evaluation of the vertebral column.
  • Having undergone surgery on the upper extremities, lower extremities, neck, and back.

Interventions

OTHERCONTROL

Pursed Lips breathing exercise, Active Respiratory Techniques Cycle, Postural Drainage, Mobilization, Calisthenic Exercises, and Patient Education. Relaxation positions and energy conservation techniques were taught in Patient Education

DEVICEPEP DEVICE

Pursed Lips breathing exercise, Active Respiratory Techniques Cycle, Postural Drainage, Mobilization, Calisthenic Exercises, and Patient Education. Relaxation positions and energy conservation techniques were taught in Patient Education PEP training was applied using the Acapella device. In addition, participants were subjected to two sessions of 10 minutes each with the Acapella device. In the study, the Acapella device, capable of sustaining expiratory flow of at least 15 L/min for 3 seconds, was activated by taking a deep breath, holding the breath for 2-3 seconds, and then exhaling into the device.

DEVICEHFCWO DEVICE

Patients were provided with conventional exercises including Pursed Lips breathing exercise, Active Respiratory Techniques Cycle, Postural Drainage, Mobilization, Calisthenic Exercises, and Patient Education. Relaxation positions and energy conservation techniques were taught in Patient Education In addition, participants will receive High-Frequency Chest Wall Oscillation (HFCWO) therapy twice a day for 10 minutes each. HFCWO training was applıed using the WEST device


Locations(1)

University of Health Sciences

Istanbul, Turkey (Türkiye)

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06274957


Related Trials